Starting in January 2019, Rio will focus on partial and full knee replacements with the potential to expand to total hip arthroplasty….
…“The real benefit is the accuracy of this machine. Now we can plan the entire surgery before we make a cut,” says Dr. Andili. “It allows us to take a step back and think of different ways to approach the surgery…
16 November 2018
Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, presented a number of compelling clinical outcomes around its flagship JOURNEY II BCS knee earlier this month at the American Association of Hip and Knee Surgeons (AAHKS). The announcement follows more than a dozen publications during the past year from various authors around the globe.1-14
In one of the largest multi-center retrospective patient cohorts ever studied, new clinical evidence represented excellent mid-term survivorship results on 2,059 patients with JOURNEY II BCS implants including:
- About 1% of patients required major revision out to 6 years.15
- No major or minor revision of any patient four years or more post-op.15
- Five year revision rate that was reported as 3.6% compared to 4.1% for the cemented posterior stabilized (PS) class in the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR).15
- Statistically significantly better survivorship for patients under 55 when compared to the Australian registry class average for the same age group at 6 years.
Cementless fixation design failures led to low use of this alternative technology. A cementless total knee arthroplasty addressed these design flaws…
…This cementless total knee arthroplasty revealed excellent clinical results at 3-year follow-up and resulted in shortened operative times. Biologic fixation was achieved in 100% of patients with improved functional and objective scores. Early results are encouraging, and this cementless total knee arthroplasty appears to provide an excellent alternative to cemented total knee arthroplasty.
Patients who underwent outpatient TKA had a slightly higher incidence of postoperative deep vein thrombosis, however results showed no differences in terms of cardiac and cerebrovascular events, acute renal failure and pulmonary events between the two groups, he said…
…While [outpatient TKA is] effective in places that have good experience and established protocols, these small differences may reflect trends from centers that have less experience with it, places where they do not do outpatient total joint [replacement] as frequently or do not have as streamlined or well-designed follow-up processes or rehabilitation protocols.
There is an ongoing worldwide temporal decline in mortality following total knee arthroplasty. Improved patient selection and perioperative care and a healthy-population effect may account for this observation. Efforts to further reduce mortality should be targeted primarily at reducing cardiovascular events following total knee arthroplasty.
December 2017 American Academy of Orthopaedic Surgeons
The American Academy of Orthopaedic Surgeons Board of Directors have approved a new “Use of Emerging Biologic Therapies” position statement highlights the importance of understanding the risks and benefits of stem cell and other biologic treatments for musculoskeletal joint conditions.
Unlike many traditional orthopedic treatments, emerging biologic therapies may not have safety and efficacy profiles, according to the statement. Since patient education is needed for informed consent, the statement includes two additional AAOS guidelines—“Orthopaedic Surgical Consent” and “Standards of Professionalism”—that reinforce the orthopedic surgeon’s role of fully informing patients of the risks and benefits of various treatments, securing patient consent before continuing with a particular modality…
…“While gaining in popularity, and providing relief for some patients, biologic treatments may lack the demonstrated safety and efficacy of many traditional orthopedic therapeutics,” J. Tracy Watson, MD, chair of the AAOS Biologics Committee, said in a press release.… Read the rest
In this lecture, Derek McMinn talks about the Birmingham Knee Replacement (BKR), addressing the need for another knee replacement option. Mr McMinn compares satisfaction results between BKR and Total Knee Replacement (TKR) patients and discusses patella tracking, the design of the BKR, post-operative knee function and knee scores. Derek McMinn MD FRCS, the pioneering surgeon and inventor of the Birmingham Knee Replacement (BKR), explores the need for an alternative to Total Knee Replacement (TKR). The principles behind the BKR are detailed and explained, showing how the BKR is designed to closely mirror the natural kinematics of the knee. Studies have shown that 20% of patients are dissatisfied with Total Knee Replacement (TKR). Patients with unicompartmental replacement are almost all delighted; however that particular arthroplasty is only applicable to a minority of patients. The BKR results show that some patients are delighted and most patients are satisfied with the outcome of their surgery.… Read the rest
NEW ORLEANS, March 6, 2018 /PRNewswire-USNewswire/ – Even with a lack of peer-reviewed evidence, the number of centers advertising stem cell therapies for osteoarthritis (OA) of the knee are increasing in the United States. These centers claim an 80 percent success rate, according to research presented this week at the 2018 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS). Of the 65 centers that provided pricing information to treat OA of the knee, the cost ranged from $1,150 to $12,000, with an average of $5,000 per injection…
…George Muschler, MD, Professor of Orthopaedic Surgery and Director at the Regenerative Medicine Laboratory at Cleveland Clinic. “Recent systematic reviews of cellular therapies for the treatment of knee OA (over 400 papers screened) have found poor levels of evidence for the efficacy of these treatments to date. Current evidence does not justify the rapid rate of growth for these therapies…”
…”The claim of “stem cell” therapy carries a high level of expectations for the potential benefits, but research is still many years away from providing clear evidence of effective treatment to patients,” said Nicolas S.… Read the rest
Posted by Melissa Chefec NEW YORK & GREENWICH, CT. (PRWEB) April 13, 2018 – Dr. Kevin Plancher with Plancher Orthopaedics & Sports Medicine with tips for understanding the pros and cons of both approaches to treating knee and hip pain.
When chronic knee or hip pain from arthritis or injury becomes a daily struggle, undergoing joint replacement surgery may become a tempting option. But is there a role for growth factors or stem cell therapy if the arthritis is mild? It’s a question orthopaedic surgeon Kevin D. Plancher, MD, is asking and attempting to answer as treatment advances offer patients options beyond what’s been available for many years.
Injections of growth factors & with stem cells – which can grow into any type of body cells – have become one of the most-researched areas of medicine, particularly in the knee and hip joint. These factors and cells are often taken from the bone marrow, fat tissue, or blood and later injected into the knee and hip to help regenerate tissues and reduce inflammation.… Read the rest